[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

JOP20190068A1 - Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy - Google Patents

Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy

Info

Publication number
JOP20190068A1
JOP20190068A1 JOP/2019/0068A JOP20190068A JOP20190068A1 JO P20190068 A1 JOP20190068 A1 JO P20190068A1 JO P20190068 A JOP20190068 A JO P20190068A JO P20190068 A1 JOP20190068 A1 JO P20190068A1
Authority
JO
Jordan
Prior art keywords
nephropathy
immunoglobulin
methods
human subject
subject suffering
Prior art date
Application number
JOP/2019/0068A
Other languages
Arabic (ar)
Inventor
Hans-Wilhelm Schwaeble
Nigel John Brunskill
Gregory A Demopulos
Tom Dudler
Original Assignee
Omeros Corp
Univ Leicester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/399,524 external-priority patent/US10736960B2/en
Priority claimed from US15/470,647 external-priority patent/US20170253667A1/en
Application filed by Omeros Corp, Univ Leicester filed Critical Omeros Corp
Publication of JOP20190068A1 publication Critical patent/JOP20190068A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21104—Mannan-binding lectin-associated serine protease-2 (3.4.21.104)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Animal Husbandry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

In one aspect, the invention provides methods for reducing proteinuria in a human subject suffering, or at risk of developing Immunoglobulin A Nephropathy (IgAN). The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory antibody effective to inhibit MASP-2-dependent complement activation.
JOP/2019/0068A 2016-10-13 2017-06-16 Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy JOP20190068A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662407979P 2016-10-13 2016-10-13
US15/399,524 US10736960B2 (en) 2016-01-05 2017-01-05 Methods for inhibiting fibrosis in a subject in need thereof
US15/470,647 US20170253667A1 (en) 2016-01-05 2017-03-27 Methods for inhibiting fibrosis in a subject in need thereof
US201762527926P 2017-06-30 2017-06-30

Publications (1)

Publication Number Publication Date
JOP20190068A1 true JOP20190068A1 (en) 2019-04-01

Family

ID=61906454

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2019/0068A JOP20190068A1 (en) 2016-10-13 2017-06-16 Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy

Country Status (18)

Country Link
EP (1) EP3525798A4 (en)
JP (1) JP6893554B2 (en)
KR (1) KR102348939B1 (en)
CN (2) CN116726163A (en)
AU (1) AU2017342428B2 (en)
BR (1) BR112019007426A2 (en)
CA (2) CA3210384A1 (en)
CL (2) CL2019000909A1 (en)
GE (1) GEP20247587B (en)
IL (1) IL265981A (en)
JO (1) JOP20190068A1 (en)
MA (1) MA46541A (en)
MX (1) MX2019004074A (en)
PH (1) PH12019500711A1 (en)
SG (1) SG11201902941UA (en)
UA (1) UA126908C2 (en)
WO (1) WO2018071701A1 (en)
ZA (1) ZA201902933B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111419860A (en) * 2020-03-19 2020-07-17 长春市儿童医院 Glomerular lobular nephropathy modeling method
CN115215937B (en) * 2021-04-15 2023-05-26 上海麦济生物技术有限公司 Anti-human MASP-2 antibody, preparation method and application thereof
EP4444758A2 (en) 2021-12-10 2024-10-16 Omeros Corporation Therapeutic antibodies that bind to the serine protease domain of masp-2 and uses thereof
CN117016486B (en) * 2023-07-20 2024-05-14 上海澎立生技医药研究有限公司 Animal model construction method for IgA nephropathy combined membranous nephropathy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE024996T2 (en) * 2003-05-12 2016-01-28 Helion Biotech Aps Antibodies to masp-2
US20140056873A1 (en) * 2004-06-10 2014-02-27 University Of Leicester Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US8840893B2 (en) * 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US7626730B2 (en) 2006-03-31 2009-12-01 Eastman Kodak Company Method of making a multilevel halftone screen
MX344322B (en) * 2009-10-16 2016-12-13 Omeros Corp Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation.
WO2012100262A1 (en) * 2011-01-21 2012-07-26 Fibrogen, Inc. Therapeutic method using anti - ctgf antibody
KR20180072851A (en) * 2011-04-08 2018-06-29 유니버시티 오브 레스터 Methods for treating conditions associated with masp-2 dependent complement activation
US9644035B2 (en) * 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
AU2012250627B2 (en) * 2011-05-04 2016-01-07 Omeros Corporation Compositions for inhibiting MASP-2 dependent complement acitivation
ES2964340T3 (en) * 2013-03-15 2024-04-05 Omeros Corp Methods for generating antibodies carrying bioactive peptides and compositions comprising the same
NZ757986A (en) * 2013-10-17 2022-07-29 Omeros Corp Methods for treating conditions associated with masp-2 dependent complement activation
EA201891570A1 (en) * 2016-01-05 2018-12-28 Юниверсити Оф Лестер METHOD OF SUPPORTING FIBROSIS IN NECESSARY IN THIS SUBJECT
JOP20170170B1 (en) * 2016-08-31 2022-09-15 Omeros Corp Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods

Also Published As

Publication number Publication date
ZA201902933B (en) 2023-05-31
CN110177557A (en) 2019-08-27
IL265981A (en) 2019-06-30
MX2019004074A (en) 2019-06-10
CA3039927A1 (en) 2018-04-19
JP6893554B2 (en) 2021-06-23
SG11201902941UA (en) 2019-05-30
JP2019534271A (en) 2019-11-28
AU2017342428B2 (en) 2021-02-04
CA3210384A1 (en) 2018-04-19
KR102348939B1 (en) 2022-01-12
CN116726163A (en) 2023-09-12
EP3525798A1 (en) 2019-08-21
EP3525798A4 (en) 2020-07-08
CL2019000909A1 (en) 2019-06-14
CL2019003485A1 (en) 2020-04-13
KR20190063475A (en) 2019-06-07
NZ753260A (en) 2021-11-26
MA46541A (en) 2019-08-21
PH12019500711A1 (en) 2019-11-18
WO2018071701A1 (en) 2018-04-19
AU2017342428A1 (en) 2019-05-23
GEP20247587B (en) 2024-01-25
CA3039927C (en) 2023-10-10
UA126908C2 (en) 2023-02-22
BR112019007426A2 (en) 2019-07-02

Similar Documents

Publication Publication Date Title
NZ753515A (en) Methods for treatment of cancer comprising tigit-binding agents
NZ738008A (en) Tigit-binding agents and uses thereof
MX2019013072A (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies.
MX2023007754A (en) Methods for inhibiting fibrosis in a subject in need thereof.
MD3204024T2 (en) Compositions comprising bacterial strains
NZ727020A (en) Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
PH12019500711A1 (en) Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy
CY1121806T1 (en) IMIDAZOPYRASINONES AS PDE1 INHIBITORS
SA518390944B1 (en) Tissue factor pathway inhibitor antibodies and uses thereof
MX2017004526A (en) Combination therapy of bispecific antibodies specific for fap and dr5 and chemotherapeutic agents.
TN2017000099A1 (en) Triazolopyrazinones as pde1 inhibitors.
GB2593097B (en) Cryptographic verification of database transactions
MX2021005394A (en) Co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies.
PH12018500578A1 (en) Methods of treating inflammatory diseases
PH12018500100A1 (en) Antibodies that bind to sortilin and inhibit the binding of progranulin
MX2018008302A (en) Therapeutic anti-cd9 antibody.
EP4273165A3 (en) Interferon beta antibodies and uses thereof
CY1122784T1 (en) HALOGONATED QUINOZOLINE-THF-AMINES AS PDE1 INHIBITORS
EP4218817A3 (en) Methods for treating metabolic diseases by inhibiting myostatin activation
EA201990903A1 (en) METHOD FOR REDUCING PROTEINURIA IN A HUMAN SUFFERING FROM IMMUNOGLOBULIN AND NEPHROPATHY
MX2018004228A (en) Antibody specifically binding to erbb3 and use thereof.
GB201800986D0 (en) Second Alzheimers treatment
EA202090453A3 (en) ANTIBODIES TO CD40
EP3385282A4 (en) Monoclonal antibodies against bambi and use for the treatment of inflammatory diseases
TN2013000045A1 (en) Anti-n3pglu amyloid beta peptide antibodies and uses thereof